Prosensa Holding NV, which is developing a therapy for Duchenne muscular dystrophy, has appointed Willem van Weperen to the new position of chief commercial officer. Mr van Weperen was previously the chief executive of to-BBB technologies BV, and before that an executive at Genzyme (Sanofi SA).
Prosensa also announced the appointment of Annalisa Jenkins, formerly an executive at Merck Serono, as a member of its supervisory board.
Prosensa announced the appointments on 30 June 2014.
Copyright 2014 Evernow Publishing Ltd